There are currently 2878 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study
NCT04973397
Recruiting
The proportion of noncardiac surgeries performed as same-day surgery is increasing worldwide, with more complex surgeries being performed on higher risk patients in the outpatient setting. Little is known on the risk factors, incidence and prognosis of patients undergoing same-day noncardiac surgery. The main objective of this study is to inform on the incidence and risk factors of cardiovascular and other adverse events after same-day surgery and to develop risk prediction tools to better infor... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
06/20/2025
Locations: MD Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Preoperative Care, Surgery--Complications, Myocardial Infarction
Register for Updates
ViDES Trial (Vitamin D Extra Supplementation)
NCT05459298
Recruiting
The objective of the study is to compare supplementation with vitamin D at 800 IU/day to usual care for the first 28 days after birth with respect to 25 (OH) vitamin D levels and indicators of likely or plausible effects of vitamin D supplementation on the function or structure of the lung, bones, immune system, and brain in extremely premature (EP) infants who are \<28 weeks gestational age (GA) or \<1000 grams of birth weight (BW). The study results will be analyzed as intention to treat Bayes... Read More
Gender:
ALL
Ages:
Between 24 hours and 96 hours
Trial Updated:
06/20/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Vitamin D Deficiency
Register for Updates
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
NCT05482893
Recruiting
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, biliary tract carcinoma (BTC) and pancreatic ductal adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: MD Anderson Cancer Center, GI Medical Oncology Dept, Houston, Texas
Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Register for Updates
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027
Recruiting
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Register for Updates
Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
NCT06066502
Recruiting
The goal of this interventional study is to compare standard mechanical ventilation to a lung-stress oriented ventilation strategy in patients with Acute Respiratory Distress Syndrome (ARDS). Participants will be ventilated according to one of two different strategies. The main question the study hopes to answer is whether the personalized ventilation strategy helps improve survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Baylor College of Medicine / St. Luke's Medical Center, Houston, Texas
Conditions: Acute Respiratory Distress Syndrome, Respiratory Failure
Register for Updates
A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study
NCT07045103
Recruiting
The ON-SITE study represents a prospective, observational study focused on the training/tuning and pivotal validation of deep learning algorithms that detect cell/tissue morphology suspicious for cancer in biopsies of peripheral lung nodules/masses and mediastinal/hilar lymph nodes imaged with the NIO Laser Imaging System in the procedure room without requiring traditional sample processing. The study includes four arms based on biopsy location and biopsy modality/tool: 1. Transbronchial force... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
06/20/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Biopsy
Register for Updates
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273
Recruiting
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Large B-cell Lymphoma
Register for Updates
Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT06795412
Recruiting
The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: University of Texas - M.D. Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumours
Register for Updates
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
NCT06108050
Recruiting
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596
Recruiting
This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection phase followed by an adaptive design continuation. The study is comprised of 2 cohorts. Cohort 1 will include participants who have not received... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Urothelial Cancer
Register for Updates
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
NCT06383572
Recruiting
To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/19/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphodepleting Chemotherapy, Myeloid Malignancies
Register for Updates
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
NCT06385886
Recruiting
The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once unaffiliated individuals are found using the pathways, Investigators will employ linkage coordinators (trained staff) to engage these patients in care. Participants will be asked to fill out an assess... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: University of Texas at Houston, Houston, Texas
Conditions: Sickle Cell Disease
Register for Updates